Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NASDAQ: AZN) reported that ENHERTU followed by paclitaxel, trastuzumab and pertuzumab achieved a 67.3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE